Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study information and are willing to sign a written consent form.
• People who are at least 18 years old.
• People who have been diagnosed through a tissue or cell sample with locally advanced or metastatic non-small cell lung cancer (a specific type of lung cancer that has spread or cannot be removed by surgery).
• People whose lung cancer has specific gene changes called EGFR mutations — specifically a deletion in exon 19 or a change called L858R in exon 21.
• People whose cancer shows high levels or extra copies of a protein/gene called c-Met, confirmed after previous treatment with a type of targeted therapy known as an EGFR-TKI.
• People who have at least one tumour that can be measured using standard imaging guidelines.
• People who are in relatively good general health, rated 0 or 1 on a standard medical scale used to measure how much a person's illness affects their daily activities (confirm with trial site).

Who may not be able to join:

• People who have previously been treated with MET inhibitors or therapies that target a protein called HGF.
• People whose cancer has specific gene changes called ALK or ROS1 mutations.
• People who have brain or central nervous system involvement that is causing symptoms, is not stable, or requires increasing doses of steroids to manage.
• People who are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.